Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memory Pharmaceuticals
• Treatments: Antipsychotic Agents

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia (any subtype), assessed using a structured interview.

• At least one month on the same dose of antipsychotic medication.

• Clinically stable, as judged by the investigator, and in a non-acute phase for at least 12 weeks.

• Able to provide informed consent.

• Fluent in English.

• Smokers and non-smokers.

Exclusion Criteria:

• First 3 years of schizophrenia diagnosis.

• Current risk of suicide, or history of suicidal behavior within the last 6 months.

• Hospitalized for psychiatric symptoms in the past 3 months.

• Other psychiatric diagnoses.

• Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months according.

• Nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix).